1. Home
  2. NRIX vs CSR Comparison

NRIX vs CSR Comparison

Compare NRIX & CSR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nurix Therapeutics Inc.

NRIX

Nurix Therapeutics Inc.

HOLD

Current Price

$18.62

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Logo D/B/A Centerspace

CSR

D/B/A Centerspace

HOLD

Current Price

$65.50

Market Cap

1.1B

Sector

Real Estate

ML Signal

HOLD

Company Overview

Basic Information
Metric
NRIX
CSR
Founded
2009
1970
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Real Estate Investment Trusts
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.1B
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
NRIX
CSR
Price
$18.62
$65.50
Analyst Decision
Strong Buy
Buy
Analyst Count
13
7
Target Price
$27.46
$70.50
AVG Volume (30 Days)
2.1M
206.1K
Earning Date
01-27-2026
11-03-2025
Dividend Yield
N/A
4.71%
EPS Growth
N/A
N/A
EPS
N/A
1.82
Revenue
$83,687,000.00
$273,450,000.00
Revenue This Year
$58.38
$6.83
Revenue Next Year
N/A
$3.14
P/E Ratio
N/A
$35.82
Revenue Growth
48.32
5.72
52 Week Low
$8.18
$52.76
52 Week High
$22.50
$69.15

Technical Indicators

Market Signals
Indicator
NRIX
CSR
Relative Strength Index (RSI) 60.48 55.12
Support Level $17.44 $63.59
Resistance Level $22.50 $66.28
Average True Range (ATR) 1.28 1.86
MACD -0.27 0.01
Stochastic Oscillator 40.12 75.15

Price Performance

Historical Comparison
NRIX
CSR

About NRIX Nurix Therapeutics Inc.

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.

About CSR D/B/A Centerspace

Centerspace is a real estate investment trust (REIT) that focuses on the ownership, management, acquisitions, redevelopment, and development of apartment communities. The company operates through a single reportable segment which includes the ownership, management, development, redevelopment, and acquisition of apartment communities and conduct their corporate operations from offices in Minot, North Dakota and Minneapolis, Minnesota.

Share on Social Networks: